Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bristol Sets Positive, But Hesitant Tone About Nivolumab Trials

This article was originally published in The Pink Sheet Daily

Executive Summary

The New York pharma talked about its anti-PD-1 drug for most of its year-end conference call, but managed to say very little about the success of the drug so far in clinical trials, disappointing analysts and investors.

You may also be interested in...



Two Approaches To PD-1 Blocker Pediatric Studies Could Help Clarify Biomarker’s Role

Merck plans to enrich its Phase II study for MK-3475 with patients whose tumors express PD-L1; Bristol would take all comers in its Phase I/II trial of nivolumab.

Big Pharma Explores New Frontier Of Lung Cancer Immunotherapy

Lung cancer wasn’t viewed traditionally as a tumor that would respond to immunotherapy. But with checkpoint inhibitor data looking promising, big pharma is diving in and prioritizing the disease, reeled in by the large patient population and high unmet need.

IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic

Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.

Topics

Related Companies

UsernamePublicRestriction

Register

PS076421

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel